What is the dosage and usage of beclomethasone (corticosteroid medication) for treating allergic rhinitis and asthma?

Beclomethasone: Dosage and Usage for Allergic Rhinitis and Asthma

Intranasal Beclomethasone for Allergic Rhinitis

For allergic rhinitis, intranasal beclomethasone is highly effective as first-line therapy, with standard dosing of 168 mcg twice daily (one spray per nostril twice daily) for adults and children ≥6 years of age. 1

Age-Specific Dosing

• Children ≥6 years and adults: 168 mcg twice daily (42 mcg per spray, one spray per nostril twice daily) 1
• Children <6 years: Safety and effectiveness have not been established; beclomethasone is not approved for this age group 1
• Alternative for younger children (2-5 years): Consider triamcinolone acetonide instead, which is approved for children ≥2 years 2

Clinical Efficacy for Rhinitis

• Intranasal beclomethasone prevented seasonal increases in bronchial responsiveness in patients with allergic rhinitis and asthma 3
• Treatment significantly reduced markers of lower airway inflammation (cysteinyl leukotrienes) in exhaled breath condensate 3
• Nasal beclomethasone at 400 mcg/day significantly reduced nasal symptoms by day 50 of treatment 4

Important Caveat for Concomitant Asthma

While intranasal corticosteroids improve rhinitis symptoms, they should NOT replace inhaled corticosteroids for asthma control—the combination of intranasal plus inhaled corticosteroids remains the current standard of care. 3

---

Inhaled Beclomethasone for Asthma

For asthma, inhaled beclomethasone (QVAR) is effective at doses ranging from 40-320 mcg twice daily, with starting doses determined by asthma severity and prior corticosteroid use. 5

Dosing by Clinical Scenario

Patients NOT Previously on Corticosteroids (Steroid-Naive)

• Mild asthma: Start with 40 mcg twice daily (80 mcg/day total) 5
• Moderate asthma: Start with 80 mcg twice daily (160 mcg/day total) 5
• Both doses significantly improved FEV1, morning peak expiratory flow, and asthma symptoms compared to placebo within 6 weeks 5

Patients Previously on Oral Corticosteroids

• Initial dose: 320 mcg daily (160 mcg twice daily) 5
• This dose provided comparable control to 672 mcg of CFC-BDP (older formulation) 5
• Critical safety point: When transitioning from oral to inhaled corticosteroids, withdraw oral steroids slowly over 9-12 months due to risk of adrenal insufficiency 6
• Patients require additional systemic corticosteroids immediately for acute exacerbations during this transition period 6

Dose Range and Titration

• Effective range: 40-320 mcg twice daily, depending on severity 5
• QVAR (HFA formulation) achieves comparable control at approximately half the dose of older CFC-BDP formulations 5
• Titrate to the lowest effective dose that controls symptoms 1

Clinical Efficacy for Asthma

• At doses of 200-600 mcg daily, beclomethasone is preferable to oral corticosteroids due to lack of systemic side effects 6
• Can allow worthwhile reduction or complete replacement of systemic corticosteroids, particularly when initial prednisone dose is <10 mg daily 6
• Improvement in lung function typically occurs within 6 weeks of treatment 5

---

Combined Rhinitis and Asthma Management

Standard Approach

Patients with both allergic rhinitis and asthma require BOTH intranasal beclomethasone (for rhinitis) AND inhaled beclomethasone (for asthma) administered separately through appropriate delivery devices. 3

• Intranasal route: Use nasal spray device for upper airway symptoms 1
• Inhaled route: Use metered-dose inhaler with spacer for lower airway control 5

Evidence for Dual Therapy

• A Cochrane review concluded that patients with allergic rhinitis and asthma treated with intranasal corticosteroids alone did not show appreciable differences in asthma outcomes compared to untreated patients 3
• The combination of intranasal plus inhaled corticosteroids should remain standard practice 3
• However, one study showed that nasal inhalation of beclomethasone (≥500 mcg/day via facemask) can simultaneously treat both conditions by delivering medication to both upper and lower airways 7

Alternative Strategy (Resource-Limited Settings)

• Nasal inhalation of beclomethasone ≥500 mcg/day through a facemask attached to a valved spacer can provide relief for both rhinitis and asthma 7
• This approach is less expensive than conventional dual therapy but is not standard practice in well-resourced settings 7

Benefits of Treating Rhinitis in Asthmatic Patients

• Intranasal beclomethasone 400 mcg/day significantly reduced asthma symptoms by day 75 and decreased bronchial hyperresponsiveness to histamine 4
• Benefits for lower airways were observed only after prolonged treatment (>75 days) 4
• Treatment of rhinitis with nasal corticosteroids can reduce asthma-related morbidity, including emergency visits and nighttime awakenings 8

---

Safety Considerations

Pediatric Growth Monitoring

• Critical warning: Intranasal beclomethasone can reduce growth velocity in children 1
• In children aged 6-9.5 years, beclomethasone 168 mcg twice daily reduced growth velocity to 4.75 cm/year versus 6.20 cm/year with placebo (P<0.01) 1
• Approximately 50% of treated children grew below the 10th percentile 1
• Monitor height routinely (via stadiometry) in all pediatric patients receiving intranasal beclomethasone 1
• Growth suppression has been reported with long-term use of beclomethasone exceeding recommended doses 2

HPA Axis Suppression

• At doses of 400-800 mcg/day (inhaled), beclomethasone has little or no adverse effect on adrenal function 6
• Intranasal beclomethasone 336 mcg once daily or 168 mcg twice daily showed no significant differences in plasma cortisol response to cosyntropin stimulation compared to placebo 9
• However, patients transitioning from oral corticosteroids require 9-12 months for HPA axis recovery 6

Common Adverse Effects

• Intranasal: Nasal irritation, epistaxis, pharyngitis, headache 1, 9
• Inhaled: Oropharyngeal candidiasis (dose-related, more common in women) 6
• Proper administration technique (directing spray away from nasal septum) reduces epistaxis risk by four-fold 2

Contraindications

• Hypersensitivity to beclomethasone or its components 1

Pregnancy and Lactation

• Pregnancy Category C: Teratogenic in animals at high doses; use only if potential benefit justifies risk 1
• Hypoadrenalism may occur in infants born to mothers receiving corticosteroids during pregnancy 1
• Nursing mothers: Caution advised as corticosteroids are excreted in human milk 1

---

Administration Technique

Intranasal Spray

• Prime bottle before first use 2
• Shake bottle prior to each use 2
• Have patient blow nose before administration 2
• Keep head upright during administration 2
• Use contralateral hand technique (right hand for left nostril) to direct spray away from septum 2
• Do not close opposite nostril during administration 2
• If using nasal saline irrigations, perform them before steroid spray 2

Inhaled Formulation

• Use metered-dose inhaler with valved spacer for optimal delivery 7
• Rinse mouth after use to reduce risk of oral candidiasis 6

---

Duration and Monitoring

Onset of Action

• Intranasal: Onset within 12 hours, maximal efficacy reached in days to weeks 2
• Inhaled: Improvement in lung function typically within 6 weeks 5
• Benefits for lower airways from intranasal treatment may require >75 days 4

Long-Term Use

• Intranasal corticosteroids do not cause rhinitis medicamentosa and are safe for long-term daily use 2
• For predictable seasonal patterns, initiate before symptom onset and continue throughout allergen exposure 2
• For moderate-to-severe rhinitis, continue with follow-up every 6 months if effective 2

When to Reassess

• If no improvement after 3 months of intranasal therapy, consider adding short course of oral corticosteroids or further evaluation 2
• Periodically examine nasal septum to monitor for mucosal erosions 2